CA3015519A1 - Method and composition for treating cancer or skin lesion using a vaccine - Google Patents

Method and composition for treating cancer or skin lesion using a vaccine Download PDF

Info

Publication number
CA3015519A1
CA3015519A1 CA3015519A CA3015519A CA3015519A1 CA 3015519 A1 CA3015519 A1 CA 3015519A1 CA 3015519 A CA3015519 A CA 3015519A CA 3015519 A CA3015519 A CA 3015519A CA 3015519 A1 CA3015519 A1 CA 3015519A1
Authority
CA
Canada
Prior art keywords
hpv
vaccine
dose
patient
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3015519A
Other languages
English (en)
French (fr)
Inventor
Tim Ioannides
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hpvvax LLC
Original Assignee
Hpvvax LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hpvvax LLC filed Critical Hpvvax LLC
Publication of CA3015519A1 publication Critical patent/CA3015519A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Anesthesiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
CA3015519A 2016-02-27 2017-02-24 Method and composition for treating cancer or skin lesion using a vaccine Pending CA3015519A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201662300785P 2016-02-27 2016-02-27
US62/300,785 2016-02-27
US201662328487P 2016-04-27 2016-04-27
US62/328,487 2016-04-27
US201662338183P 2016-05-18 2016-05-18
US62/338,183 2016-05-18
US201762444576P 2017-01-10 2017-01-10
US62/444,576 2017-01-10
US201762455434P 2017-02-06 2017-02-06
US62/455,434 2017-02-06
PCT/US2017/019433 WO2017147475A1 (en) 2016-02-27 2017-02-24 Method and composition for treating cancer or skin lesion using a vaccine

Publications (1)

Publication Number Publication Date
CA3015519A1 true CA3015519A1 (en) 2017-08-31

Family

ID=59686556

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3015519A Pending CA3015519A1 (en) 2016-02-27 2017-02-24 Method and composition for treating cancer or skin lesion using a vaccine

Country Status (16)

Country Link
EP (1) EP3419661A4 (enExample)
JP (3) JP2019506435A (enExample)
KR (1) KR102873848B1 (enExample)
CN (1) CN108883168A (enExample)
AU (1) AU2017223970B2 (enExample)
BR (1) BR112018067550A2 (enExample)
CA (1) CA3015519A1 (enExample)
CL (1) CL2018002438A1 (enExample)
CO (1) CO2018009205A2 (enExample)
HK (1) HK1256935A1 (enExample)
IL (1) IL261340B2 (enExample)
MX (1) MX2018010338A (enExample)
MY (1) MY194694A (enExample)
SG (1) SG11201807080UA (enExample)
WO (1) WO2017147475A1 (enExample)
ZA (1) ZA201805679B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114127095B (zh) * 2019-07-19 2024-04-09 神州细胞工程有限公司 嵌合的人乳头瘤病毒11型l1蛋白
JP2023546073A (ja) * 2020-10-12 2023-11-01 エイチピーブイヴァックス，リミテッド ライアビリティー カンパニー． 第１の治療有効成分としてのワクチンを、第２の有効成分と組み合わせて使用する、癌を治療するための組成物及び方法
KR20250089555A (ko) * 2022-10-31 2025-06-18 파이로자스 인크 면역요법 조성물 및 사용 방법

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0110431D0 (en) * 2001-04-27 2001-06-20 Glaxosmithkline Biolog Sa Novel compounds
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206359D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US9724404B2 (en) * 2009-04-13 2017-08-08 INSERM (Institut National de la Santé et de la Recherche Médicale) HPV particles and uses thereof
CN101890160B (zh) * 2009-04-28 2014-06-18 北京康乐卫士生物技术有限公司 多价重组人乳头瘤病毒疫苗及其应用
US20120087937A1 (en) * 2009-06-25 2012-04-12 Brigitte Desiree Alberte Colau Novel compositions
US8809562B2 (en) * 2011-06-06 2014-08-19 Chevron Phillips Chemical Company Lp Use of metallocene compounds for cancer treatment
US20130064849A1 (en) * 2011-07-14 2013-03-14 The Board Of Regents Of The University Of Texas Methods to treat and prevent cardiovascular disease using human papillomavirus vaccines
US20150110824A1 (en) * 2012-03-18 2015-04-23 Glaxosmithkline Biologicals, Sa Method of vaccination against human papillomavirus
US20130251782A1 (en) * 2012-03-22 2013-09-26 Leo Laboratories Limited Topical application of ingenol mebutate with occlusion
US20140275082A1 (en) * 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US9974849B2 (en) * 2013-10-13 2018-05-22 Bioventures, Llc Human Papilloma virus therapeutic vaccine
AU2015204503B2 (en) * 2014-01-13 2020-07-09 Baylor Research Institute Novel vaccines against HPV and HPV-related diseases
CN107001430A (zh) * 2014-10-24 2017-08-01 哈普威克斯有限责任公司 癌症和皮肤病变治疗

Also Published As

Publication number Publication date
JP2019506435A (ja) 2019-03-07
CO2018009205A2 (es) 2018-09-20
ZA201805679B (en) 2019-11-27
MY194694A (en) 2022-12-15
EP3419661A1 (en) 2019-01-02
JP2023110038A (ja) 2023-08-08
WO2017147475A1 (en) 2017-08-31
KR20180112043A (ko) 2018-10-11
HK1256935A1 (zh) 2019-10-04
EP3419661A4 (en) 2019-10-23
SG11201807080UA (en) 2018-09-27
AU2017223970A1 (en) 2018-09-13
BR112018067550A2 (pt) 2019-10-01
IL261340A (en) 2018-11-29
IL261340B2 (en) 2023-07-01
JP7732784B2 (ja) 2025-09-02
MX2018010338A (es) 2018-11-09
KR102873848B1 (ko) 2025-10-17
CN108883168A (zh) 2018-11-23
AU2017223970B2 (en) 2022-01-27
IL261340B1 (en) 2023-03-01
JP2021155448A (ja) 2021-10-07
CL2018002438A1 (es) 2019-01-04

Similar Documents

Publication Publication Date Title
JP7732784B2 (ja) ワクチンを使用して癌または皮膚病変を治療するための方法および組成物
EP3273955B1 (en) Treatment of respiratory diseases
US20240226213A1 (en) Treatment of Warts
US10799574B2 (en) Method and composition for treating cancer or skin lesion using a vaccine
US11813329B2 (en) Method and composition for treating cancer or skin lesion using a vaccine
AU2021360676B2 (en) Composition and method for treating cancer using a vaccine as a first therapueutic active ingredient in combination with a second active ingredient
CN115463118A (zh) 和厚朴酚在制备治疗或预防毛细血管瘤的药物中的用途
CA3219273A1 (en) Use of 5-nitro-8-hydroxyquinoline
US20230414741A1 (en) Method and compositon for treating cancer using a vaccine
US20220105082A1 (en) New formulations containing leukotriene receptor antagonists
CN116115760A (zh) Eed抑制剂在制备治疗神经免疫性疾病药物中的应用
WO2022206086A1 (zh) 靶向灭活疱疹病毒膏贴药物组合物及其制备方法与应用
RU2147841C1 (ru) Способ лечения папилломатоза гортани
AU2015335652B2 (en) Cancer and skin lesion treatment
CN116768982B (zh) 一种多肽及其在制备防治肿瘤的药物中的应用
RU2681546C1 (ru) Способ экстренной профилактики клещевого вирусного энцефалита
WO2022264097A1 (en) Pharmaceutical composition of anti-tumour necrosis factor (anti-tnf) agent for management of infectious diseases caused by coronaviruses
TWI418347B (zh) 治療疱疹病毒感染的方法
TW202511290A (zh) 一種重組抗ＩＬ－２３ｐ１９抗體治療中重度銀屑病的方法
CN118948873A (zh) 金线莲苷在防治脑胶质瘤中的应用
CN107308145A (zh) 苯乙双胍作为皮肤抗炎制剂的用途
HK1241898A1 (en) Cancer and skin lesion treatment

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220223

EEER Examination request

Effective date: 20220223

EEER Examination request

Effective date: 20220223

EEER Examination request

Effective date: 20220223

EEER Examination request

Effective date: 20220223

EEER Examination request

Effective date: 20220223